Clusterin dosage and evidence
Written by Aaron CuhaReviewed Sep 2026
The short answer
Clusterin is a blood protein that goes up with exercise. In old mice and in mice with an Alzheimer-like illness, it calmed brain inflammation. It is higher in people who exercise. The only trials in people that changed it on purpose pushed it down, for cancer, and one stopped early.
Evidence grade for Clusterin: Preliminary. The rule: studied in people, but no published study has had people take it. The sum on this page: 2 human studies where nobody was given it, 1 registered with no result. A grade counts how much has been done to people, not whether it works.
- People given it
- 0
- Human studies
- 0
- Found nothing
- 0
Dose
No human dose established
No published study on this page has given this compound to people and reported a result.
2 human studies where nobody was given it, 1 registered with no result
4 effects reported, 4 unwanted, by people using it, not a trial
Goal pages: Brain, memory and mood, Injury, healing and recovery, Immune system and inflammation, Gut health
In plain English
In plain English, from Aaron
This is how I would explain it to a friend. The evidence, with the numbers, is further down the page.
This is a blood protein that goes up when you exercise. It helps keep other proteins from clumping, and it puts a brake on part of the immune system. In mice it calmed brain inflammation.
What people take it for
- Lower brain inflammation.
- Protection against Alzheimer disease.
- The benefits of exercise in a bottle.
What studies in people showed
Nobody has been given this as a treatment. The only trials that changed it on purpose pushed it down, not up. That drug, custirsen, was built for cancer. Its late stage study stopped after 14 people, because of a rule about who could join. Quoting that record as support for the exercise idea gets the data backwards. In people, one observation stands: those with memory problems who did six months of structured exercise had more of it in their blood. The CLU gene is also a known Alzheimer risk gene. In mice, injecting it into a vein quietened inflammation genes in the brain.
What people report
Reports, not study results
The good
- We have not collected user reports on this one yet.
The bad
- There is no safety data for giving this to a person at all.
- Exercise changes hundreds of blood proteins at once, so the human link proves nothing about this one.
- Its gene is tied to Alzheimer risk in ways that do not map onto more being better.
- The protein turns up inside the sticky plaques found in Alzheimer disease.
Where these come from: The exercise observation, the genetics and the cancer drug record come from the studies on this page. No user reports exist.
My bottom line
Nice mouse work, and the only drug ever aimed at it pushed the other way. Exercise is the version that is actually available.
An opinion, not a finding. I am a coach, not a doctor.
What it has been measured to do
Animal and lab work, not yet tested in people
Real results, but from animals or cells, not people. What works in a mouse often does not work the same way in a person. Nobody can patent this, so nobody would ever earn back the cost of a study in people. That is usually why there is none. The record on this one is set out below.
- Inflammation1 animal or lab study
- Memory and thinking1 animal or lab study
34 of the 36 indexed goals have no study of any kind behind Clusterin
No study in people, animals or cells on this page reports a result for these. That does not prove Clusterin does nothing for them. It does mean anything you have heard about Clusterin and one of these did not come from a study cited here.
Show full evidence
What is Clusterin?
Clusterin is a blood protein that goes up with exercise. In old mice and in mice with an Alzheimer-like illness, it calmed brain inflammation. It is higher in people who exercise. The only trials in people that changed it on purpose pushed it down, for cancer, and one stopped early.
Nobody has been given clusterin as a treatment.
The record in people runs the opposite way to the exercise idea, and should never be quoted as supporting it. The only clusterin drug that has been tested in people is custirsen, which lowers clusterin. It was built for cancer. Its late-stage study in men with advanced prostate cancer, NCT01083615, stopped after 14 of the planned people joined. The registry gives the reason as trouble signing people up, because of a rule about their pain being steady at the start. Lowering clusterin in cancer patients tells you nothing about raising it in older people. And a study that stopped early tells you little about either.
Clusterin does have a real human genetics record, older than all of this. CLU is one of the known Alzheimer disease risk genes found by scanning whole genomes, and its versions have been studied for how they combine with other risk genes. That is human evidence about clusterin, but it is about who gets the disease, not about giving anyone the protein.
A 2021 Nature paper took plasma from mice that chose to run and gave it to mice that did not. Inflammation genes in the brain quietened down, both at rest and after inflammation was triggered. Protein screening found a coordinated rise in a set of brakes on the complement system, part of the immune system, with clusterin among them. Clusterin injected into a vein stuck to the cells lining blood vessels in the brain and quietened those same genes, in mice with brain inflammation and in a mouse model of Alzheimer disease. The same paper reports one human observation. People with memory problems who did six months of structured exercise had more clusterin in their blood.
How does Clusterin work?
In mice, clusterin injected into a vein sticks to the cells lining blood vessels in the brain and quietens inflammation genes there, both in a fast brain inflammation model and in an Alzheimer model. In the same paper, exercising animals show a coordinated rise in a set of brakes on the complement system, part of the immune system. That fits clusterin's long known job as a complement brake and as a helper that keeps other proteins from clumping outside cells. In people, its known biology is the same: a secreted helper protein, a complement regulator, and a protein that travels with blood fats. The CLU gene is a known Alzheimer risk gene. The calming effect seen in mice has not been tested in a person.
What have studies in people found about Clusterin?
Nobody has been given clusterin. The human data are measurements in exercise and weight studies, human genetics linking the CLU gene to Alzheimer risk, and a cancer programme that lowered clusterin rather than raising it.
- The only clusterin drug ever given to people is custirsen, which lowers clusterin. It was built for prostate and breast cancer. Its registered late-stage study NCT01083615 stopped after 14 people, because of a rule about who could join, not because of a safety or benefit result. Lowering clusterin is the opposite of the exercise idea, and this must not be quoted as support for it.
- Nature 2021, the human part: people with memory problems who did six months of structured exercise had more clusterin in their blood. That is a measurement inside an otherwise mouse study.
- NCT04133896: a study of 176 people comparing those with obesity to those without, measuring three blood proteins including clusterin. Measurement only, and it is finished.
- Human genetics: CLU is a known Alzheimer risk gene from whole-genome scans, and its versions have been studied for how they combine with other risk genes.
What this does not tell you: More clusterin in people who exercised for six months does not tell you clusterin caused anything. Exercise changes hundreds of blood proteins at once. The genetics tell you the CLU gene affects Alzheimer risk, not that giving someone clusterin would help. And the only time this protein was targeted in people, the drug pushed it the other way, in cancer patients, and the study stopped early. There is no safety data at all for giving clusterin to a person.
The state of the research
Clusterin is a clean example of why a page has to say which way a treatment pushes. Search for clusterin trials and you will find a real programme in people, with early, middle and late stage records attached. All of it is custirsen, a drug built to lower clusterin in cancer. The exercise idea says higher clusterin protects. Quoting the cancer record as support for the exercise idea gets the data backwards, and that mistake is easy to make from a registry search alone.
The mouse work itself is reasonably careful. Move the plasma first. Then find the protein. Then give the protein on its own and see the same calming of inflammation in two different models. What is missing is what is missing for every factor in this batch. Nobody has given it to a person.
One thing about clusterin makes a programme in people less likely than it looks. Because the CLU gene is a known Alzheimer risk gene, clusterin's role in people is already known to be complicated and to run both ways. The protein turns up inside the sticky plaques, and its gene versions are tied to risk in ways that do not map neatly onto more being better.
The evidence, in charts
Fig. 1a · how many people
176people, across 1 study in people cited here
| Study | People | Share |
|---|---|---|
| ClinicalTrials.gov 2018 | 176 | 100% |
The whole total is one study of 176. Counts are the number of people each study on this page says it signed up. That includes studies that only watched people and gave nobody the compound. 2 more studies in people give no headcount and are not counted here. Studies still signing people up are left out, and only studies cited on this page are counted.
Fig. 1b · evidence mix
3 of 4 sources here are studies in people. The rest is not.
- Study in people · done in people375%
- Animal study · done in animals125%
Counted from the list of sources on this page. It counts only what we cite, so there may be more studies out there. A review counts once, however many studies it sums up.
Fig. 2 · evidence over time
The studies cover 4 different years, 2010 to 2021, counted from the list of sources on this page.
Fig. 3 · legal status at a glance
US
Not approved
UK
Not approved
AU
Not approved
CA
Not approved
Not approved in any of the four countries shown. This is what the law says, not a verdict on the science. See Legal status below for the full text and any notes.
Fig. 4 · how much does what
Nobody has tested different amounts in people
This chart would show how the effect changes as the amount goes up. For this compound, nobody has measured that in people. So we leave it empty. We will not borrow an animal chart and pretend it works the same in people.
Fig. 5 · what the molecule is
- Kind of compound
- Biologic
- Molecule weight
- Not on file
- Half-life
- None on file
- Chain length
- None on file
No amino acid sequence is on file for Clusterin, so none is drawn rather than guessed from a name.
The studies we cite
- Study in people2016Interaction between variants in CLU and MS4A4E modulates Alzheimer's disease risk
This is about inherited risk, not about taking clusterin. Researchers tested whether two gene variants interact to change Alzheimer disease risk, using 3,837 people with the disease and 4,145 without. The interaction held up. Carrying both risk versions raises risk more than either alone, and the combination ranks among the strongest known outside a small handful of genes. The authors estimate Alzheimer cases would fall about 8% if nobody carried them. Nobody was given clusterin.
Human genetics. CLU, the clusterin gene, is an established Alzheimer disease risk locus, and this study examines how variants in CLU interact with variants in MS4A4E to modulate that risk. Human evidence about clusterin biology, but about inherited disease risk rather than about administering the protein.
- Study in people2018Circulating IL-6, Clusterin and Irisin in Obese Subjects
This record measures clusterin in people. It does not give it to anyone. 176 people took part in an observational study comparing those with obesity to those without, with blood drawn at a single point in time. It started in February 2018 and is marked completed. Measuring a protein in blood tells you what the body already makes. It says nothing about what injecting it would do.
Registry record for human clusterin measurement. Observational case-control study with a cross-sectional time perspective, 176 participants enrolled, completed, start February 2018. Measurement in people, not administration.
- Study in people2010A Study Evaluating the Pain Palliation Benefit of Adding Custirsen to Docetaxel Retreatment or Cabazitaxel as Second Line Therapy in Men With Metastatic Castrate Resistant Prostate Cancer
The only human trial that deliberately changed clusterin pushed it down, not up. Custirsen is a drug that lowers clusterin, and this phase 3 study tested it in men with advanced prostate cancer. It was terminated after 14 people, with the registry giving difficulty enrolling as the reason. Achieve Life Sciences sponsored it, starting in March 2010. Note the direction. The exercise story wants more clusterin. The drug developed against a disease removes it.
The human interventional clusterin record, and it runs the opposite way to the exercise hypothesis. Custirsen is an antisense oligonucleotide that LOWERS clusterin. This phase 3 was TERMINATED with the registry reason given as inability to enrol due to criteria for stable baseline pain, after 14 participants. Sponsor Achieve Life Sciences, start March 2010.
- Animal study2021Exercise plasma boosts memory and dampens brain inflammation via clusterin
In mice, with one human measurement inside it. Plasma from mice that chose to run, given to mice that did not, quietened inflammation genes in the brain. Protein screening showed a rise in a set of immune system brakes, clusterin among them. Clusterin injected into a vein stuck to the lining of brain blood vessels and quietened those genes, in two different models. Separately, people with memory problems who did six months of structured exercise had more clusterin in their blood.
Mouse, with a human observational component. Plasma from voluntarily running mice infused into sedentary mice reduced baseline neuroinflammatory gene expression and experimentally induced brain inflammation. Proteomics showed a coordinated increase in complement cascade inhibitors including clusterin. Intravenous clusterin bound brain endothelial cells and reduced neuroinflammatory gene expression in acute brain inflammation and Alzheimer models. Separately, patients with cognitive impairment who completed six months of structured exercise had higher plasma clusterin. NIH funded.
Common questions
Has Clusterin been tested in people?
Not in a completed trial cited here. 2 human studies where nobody was given it, 1 registered with no result. Clusterin is a blood protein that goes up with exercise. In old mice and in mice with an Alzheimer-like illness, it calmed brain inflammation. It is higher in people who exercise. The only trials in people that changed it on purpose pushed it down, for cancer, and one stopped early.
What is the Clusterin dosage?
No human dose established. No published study on this page has given this compound to people and reported a result. 2 human studies where nobody was given it, 1 registered with no result
Is Clusterin FDA-approved?
Clusterin has never been given to a person as a treatment, and it is not approved anywhere. The only drug aimed at clusterin to reach human studies is custirsen. It lowers clusterin, was developed for cancer, and is not approved.
Does clusterin reduce brain inflammation in people?
Not shown. In mice, clusterin injected into a vein stuck to the cells lining brain blood vessels and quietened inflammation genes, in a fast inflammation model and in an Alzheimer model. In people, the only related observation is that those with memory problems who exercised for six months had more clusterin in their blood. That is a link inside an exercise study.
Are there clusterin trials in humans?
There are trials of a drug that lowers clusterin, which is the opposite direction. Custirsen was built for prostate and breast cancer. Its registered late-stage study NCT01083615 stopped after 14 people because of a rule about who could join. No trial has given clusterin to anyone.
Is clusterin linked to Alzheimer disease?
Yes, through genetics. CLU is one of the known Alzheimer risk genes found by scanning whole genomes, and its versions have been studied for how they combine with other risk genes. That is a risk link across populations. It is not evidence that giving clusterin would treat anything.